Effects of the Anti-CD20 Antibody Rituximab on B Cells in Human Secondary Lymphoid Organs

被引：0
|
作者：
Kamburova, E. [1 ]
Borgman, K. [1 ]
Hans, K. [1 ]
ten Berge, I [2 ]
Joosten, I [1 ]
Hilbrands, L. [3 ]
机构：
[1] Radboud Univ Nijmegen, Med Ctr, Lab Med, Lab Med Immunol, Nijmegen, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Nephrol, Amsterdam, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Nephrol, Nijmegen, Netherlands
来源：
TRANSPLANTATION | 2012年 / 94卷 / 10期
关键词：
D O I：
10.1097/00007890-201211271-00310
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
929
引用
收藏
页码：167 / 167
页数：1
相关论文
共 50 条
  • [31] Successful treatment of refractory Evan syndrome with anti-CD20 antibody (rituximab)
    Recht, M
    PEDIATRIC RESEARCH, 2003, 53 (04) : 299A - 299A
  • [32] Inflammatory microenvironment rescues B-Cells of tertiary lymphoid organs from anti-CD20 therapy during chronic antibody-mediated rejection.
    Thaunat, Olivier
    Patey, Natacha
    Gautreau, Chantal
    Nicoletti, Antonino
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 448 - 448
  • [33] Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
    Tallantyre, E. C.
    Whittam, D. H.
    Jolles, S.
    Paling, D.
    Constantinesecu, C.
    Robertson, N. P.
    Jacob, A.
    JOURNAL OF NEUROLOGY, 2018, 265 (05) : 1115 - 1122
  • [34] Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)
    Arzoo, K
    Sadeghi, S
    Liebman, HA
    ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (10) : 922 - 924
  • [35] Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
    E. C. Tallantyre
    D. H. Whittam
    S. Jolles
    D. Paling
    C. Constantinesecu
    N. P. Robertson
    A. Jacob
    Journal of Neurology, 2018, 265 : 1115 - 1122
  • [36] Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris
    Faurschou, Annesofie
    Gniadecki, Robert
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2008, 47 (03) : 292 - 294
  • [37] Rituximab (anti-CD20 monoclonal antibody) administration in a young patient with resistant B-prolymphocytic leukemia
    Vartholomatos, G
    Tsiara, S
    Christou, L
    Panteli, A
    Kaiafas, P
    Bourantas, KL
    ACTA HAEMATOLOGICA, 1999, 102 (02) : 94 - 98
  • [38] Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis
    Bhatia, A
    Ell, PJ
    Edwards, JCW
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (07) : 1099 - 1100
  • [39] Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma
    Heinzerling, L
    Dummer, R
    Kempf, W
    Schmid, MH
    Burg, G
    ARCHIVES OF DERMATOLOGY, 2000, 136 (03) : 374 - 378
  • [40] Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 antibody Rituximab.
    Giagounidis, AAN
    Anhuf, J
    Schneider, P
    Germing, U
    Soehngen, D
    Quabeck, K
    Aul, C
    BLOOD, 2001, 98 (11) : 523A - 523A
12345